Id: acc0546
Group: 1sens
Protein: CREB
Gene Symbol: CREB1
Protein Id: P16220
Protein Name: CREB1_HUMAN
PTM: phosphorylation
Site: Ser133
Site Sequence: LNDLSSDAPGVPRIEEEKSEE
Disease Category: Cancer
Disease: Ovarian Cancer
Disease Subtype:
Disease Cellline: OVCAR-3
Disease Info:
Drug: roflumilast
Drug Info: Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor approved for the treatment of severe chronic obstructive pulmonary disease (COPD) to reduce the risk of exacerbations in patients with chronic bronchitis and a history of frequent exacerbations.
Effect: increase
Effect Info: "Roflumilast induces the phosphorylation of CREB, thereby activating the cAMP/PKA/CREB pathway, enhancing the sensitivity of cisplatin (DDP)-sensitive ovarian cancer cells to DDP and reversing the DDP resistance of DDP-resistant ovarian cancer cells. "
Note:
Score: 5.0
Pubmed(PMID): 30069985
Sentence Index:
Sentence:

Sequence & Structure:

MTMESGAENQQSGDAAVTEAENQQMTVQAQPQIATLAQVSMPAAHATSSAPTVTLVQLPNGQTVQVHGVIQAAQPSVIQSPQVQTVQISTIAESEDSQESVDSVTDSQKRREILSRRPSYRKILNDLSSDAPGVPRIEEEKSEEETSAPAITTVTVPTPIYQTSSGQYIAITQGGAIQLANNGTDGVQGLQTLTMTNAAATQPGTTILQYAQTTDGQQILVPSNQVVVQAASGDVQTYQIRTAPTSTIAPGVVMASSPALPTQPAEEAARKREVRLMKNREAARECRRKKKEYVKCLENRVAVLENQNKTLIEELKALKDLYCHKSD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

CREB1-Ser108
Cancer Intensity
BRCA
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
CREB1-Ser111
Cancer Intensity
BRCA -0.935
COAD 0.719
HGSC
ccRCC -0.651
GBM
HNSC 1.355
LUAD -0.796
LUSC -0.759
non_ccRCC
PDAC
UCEC 1.067
CREB1-Ser142
Cancer Intensity
BRCA 1.677
COAD -0.547
HGSC -0.852
ccRCC -0.202
GBM
HNSC -1.472
LUAD 0.449
LUSC 0.862
non_ccRCC
PDAC
UCEC 0.086
CREB1-Ser143
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CREB1-Ser270
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
CREB1-Ser271
Cancer Intensity
BRCA 0.671
COAD 0.307
HGSC -2.002
ccRCC
GBM
HNSC
LUAD 0.269
LUSC
non_ccRCC 0.591
PDAC
UCEC 0.164
CREB1-Ser340
Cancer Intensity
BRCA
COAD 0.347
HGSC 0.586
ccRCC
GBM 1.14
HNSC
LUAD
LUSC -1.245
non_ccRCC
PDAC -0.829
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 133 D Alzheimer's disease Phosphorylation 23266915
S 133 P Duodenal cancer Phosphorylation 12220644
S 133 P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 22710715
S 133 P Lung adenocarcinoma Phosphorylation 37407566
S 133 U Multiple sclerosis Phosphorylation 33661276
S 133 U Status epilepticus Phosphorylation 33661276
S 133 U Acute myeloid leukemia Phosphorylation 35322464
S 133 U Prostate cancer Phosphorylation 12900420 ;  12900420 ;  33846571
S 133 U Gastric cancer Phosphorylation 37409440
S 133 U Synovial sarcoma Phosphorylation 35556229
S 133 U Uveal melanoma Phosphorylation 32864007

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: